XML 32 R9.htm IDEA: XBRL DOCUMENT v3.19.2
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS
6 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

Composition of Certain Financial Statement Captions

Components of selected captions in the consolidated condensed balance sheets consisted of the following (in millions):
 
June 30, 2019
 
December 31, 2018
Inventories
 
 
 
Raw materials
$
120.7

 
$
111.5

Work in process
164.4

 
144.8

Finished products
339.8

 
350.7

 
$
624.9

 
$
607.0



At June 30, 2019 and December 31, 2018, $128.6 million and $106.5 million, respectively, of the Company's finished products inventories were held on consignment. During the three months ended June 30, 2019, the Company recorded a $46.2 million charge to "Cost of Sales," primarily comprised of the write off of inventory related to strategic decisions regarding its transcatheter aortic valve portfolio, including the decision to discontinue its CENTERA program.

 
June 30, 2019
 
December 31, 2018
Accounts payable and accrued liabilities
 

 
 

Accounts payable
$
151.0

 
$
134.0

Employee compensation and withholdings
197.8

 
226.1

Taxes payable (Note 14)
14.6

 
31.3

Property, payroll, and other taxes
39.2

 
39.5

Research and development accruals
55.8

 
48.9

Accrued rebates
82.5

 
80.0

Fair value of derivatives
4.6

 
4.4

Accrued marketing expenses
15.5

 
22.3

Litigation and insurance reserves
19.0

 
196.7

Accrued relocation costs
13.0

 
11.3

Accrued professional services
9.4

 
11.0

Accrued realignment reserves
17.0

 
6.8

Other accrued liabilities
53.8

 
64.3

 
$
673.2

 
$
876.6



Supplemental Cash Flow Information
(in millions)
 
Six Months Ended   
June 30,
 
2019
 
2018
Cash paid during the year for:
 
 
 
Income taxes
$
45.2

 
$
195.1

Amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from operating leases
$
12.7

 
$

Non-cash investing and financing transactions:
 

 
 

Fair value of shares issued in payment for contingent consideration liabilities
$

 
$
34.3

Right-of-use assets obtained in exchange for new lease liabilities
$
23.5

 
$

Capital expenditures accruals
$
21.8

 
$
14.5